In the first year of the study inclusion, PD-L1 expression ≥1% on PCa cells by immunohistochemistry was also a qualifying criterium for immunotherapy eligibility, and nine patients received PD-(L)1i based on PD-L1 expression alone. Here, CD274 is linked to posterior cortical atrophy.